Economic Affairs Director Of Japan’s MHLW Comments On Daiichi Sankyo's Buyout Of Ranbaxy
This article was originally published in PharmAsia News
Executive Summary
Commenting on Daiichi Sankyo's buyout of Ranbaxy, Toshihiko Takeda, the economic affairs director of the Ministry of Health, Labor and Welfare's Health Policy Bureau, said he was surprised but thought as a new drug developer, Daiichi Sankyo took a step in the right direction to further expand overseas in a more competitive market. Even though it is still too early to judge how the generics market will develop in Japan, if after the merger Daiichi Sankyo decides to enter the generics market in Japan, it will have credibility as a major drug maker combined with low production costs in India. The legitimacy of the company's generics unit could contribute to the expansion of generic utilization in Japan. (Click here for more - Japanese language) "Economic Affairs Director Toshihiko Takeda Comments on Daiichi Sankyo's Buyout Of Ranbaxy" - Yakuji News (6/11/08)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.